Head and Neck Cancer Recurrence and Mortality in Nonselective Cyclooxygenase Inhibitor Users | Genetics and Genomics | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Blanke  C Role of COX-2 inhibitors in cancer therapy.  Cancer Invest 2004;22271- 282PubMedGoogle ScholarCrossref
Park  SWLee  SGSong  SH  et al.  The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines.  Int J Cancer 2003;107729- 738PubMedGoogle ScholarCrossref
Lin  DTSubbaramaiah  KShah  JP  et al.  Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.  Head Neck 2002;24792- 799PubMedGoogle ScholarCrossref
Wang  Z The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors.  Curr Pharm Des 2005;111771- 1777PubMedGoogle ScholarCrossref
Itoh  SMatsui  KFuruta  ITakano  Y Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor.  Oral Oncol 2003;39829- 835PubMedGoogle ScholarCrossref
Terakado  NShintani  SYano  J  et al.  Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma.  Oral Oncol 2004;40383- 389PubMedGoogle ScholarCrossref
Lang  SZeidler  R Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.  Int J Immunopathol Pharmacol 2003;16 ((2)(suppl)) 41- 48PubMedGoogle Scholar
Hashitani  SUrade  MNishimura  N  et al.  Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.  Int J Oncol 2003;23665- 672PubMedGoogle Scholar
Sumitani  KKamijo  RToyoshima  T  et al.  Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production.  J Oral Pathol Med 2001;3041- 47PubMedGoogle ScholarCrossref
Gallo  OMasini  EBianchi  B  et al.  Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.  Hum Pathol 2002;33708- 714PubMedGoogle ScholarCrossref
Rigas  BKashfi  K Cancer prevention: a new era beyond cyclooxygenase-2.  J Pharmacol Exp Ther 2005;3141- 8PubMedGoogle ScholarCrossref
Simon  LS The COX-2 inhibitors: a reasoned review of the data.  Swiss Med Wkly 2005;135419- 424PubMedGoogle Scholar
Harris  REBeebe-Donk  JDoss  HBurr Doss  D Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade.  Oncol Rep 2005;13559- 583PubMedGoogle Scholar
Samoha  SArber  N Cyclooxygenase-2 inhibition prevents colorectal cancer: from the bench to the bed side.  Oncology 2005;69(suppl 1)33- 37PubMedGoogle ScholarCrossref
Das  UN COX-2 inhibitors and metabolism of essential fatty acids.  Med Sci Monit 2005;11RA233- RA237PubMedGoogle Scholar
Minter  HAEverson  JWHuntley  S  et al.  The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.  Clin Cancer Res 2003;91885- 1897PubMedGoogle Scholar
Wang  ZFuentes  CFShapshay  SM Antiangiogenic and chemopreventative activities of celecoxib in oral carcinoma cells.  Laryngoscope 2002;112839- 843PubMedGoogle ScholarCrossref
Original Article
January 2007

Head and Neck Cancer Recurrence and Mortality in Nonselective Cyclooxygenase Inhibitor Users

Author Affiliations

Author Affiliations: Departments of Otolaryngology–Head and Neck Surgery (Drs Gillespie, Moody, Lee, Poole, Hornig, Lathers, Young, and Day) and Medicine (Dr Young), Medical University of South Carolina, Charleston; and Department of Otolaryngology–Head and Neck Surgery (Drs Gillespie and Moody) and Research Service (Drs Young and Lathers), Ralph H. Johnson Veterans Affairs Medical Center, Charleston.

Arch Otolaryngol Head Neck Surg. 2007;133(1):28-31. doi:10.1001/archotol.133.1.28

Objective  To determine whether ongoing use of a cyclooxygenase (COX) inhibitor is associated with a reduction in mortality and disease recurrence after head and neck cancer treatment.

Design  Retrospective case-control study.

Patients  A total of 325 potential subjects with head and neck squamous cell carcinoma were identified using an electronic patient database.

Main Outcome Measure  The rate of COX inhibitor use among patients who had died or whose disease had recurred (cases) was compared with the rate of use among survivors or those without recurrence (controls). The comparison was controlled for tumor site, tumor stage, treatment received, age, sex, race, smoking, and alcohol use.

Results  The 325 patients were compared by logistic regressions, with recurrence rate and survival status as the dependent variables. There was no difference in COX inhibitor exposure between patients with recurrence and those with no recurrence (P = .42) or between survivors and those who died of disease (P = .66). The median survival of COX inhibitor users, however, was 96 months, compared with 47 months in nonusers. The only independent variable with a significant impact on recurrence and survival was tumor stage at the time of diagnosis.

Conclusions  Although preliminary in vitro studies suggest an antitumor effect of COX inhibitors in head and neck cancer, this study found no difference in head and neck cancer recurrence or survival in nonselective COX inhibitor users vs nonusers. A randomized, double-blinded controlled trial is needed to determine if COX inhibitors are an effective chemopreventive therapy in patients with head and neck cancer.